Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved dermatological treatments, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Claude Maraoui, President and CEO, will present a corporate overview available for on-demand viewing starting September 9, 2024, at 7:00 a.m. ET.
The company will also engage in one-on-one meetings during the conference. Investors can access a replay of the presentation on Journey Medical's website for approximately 30 days after the event, providing an opportunity to gain insights into the company's strategies and performance in the dermatological pharmaceutical market.
Journey Medical (Nasdaq: DERM), una società farmaceutica in fase commerciale specializzata in trattamenti dermatologici approvati dalla FDA, ha annunciato la sua partecipazione alla 26ª Conferenza Globale sugli Investimenti Annuale H.C. Wainwright. Claude Maraoui, Presidente e CEO, presenterà una panoramica aziendale disponibile per la visione on-demand a partire da 9 settembre 2024, alle 7:00 ET.
La società parteciperà inoltre a incontri individuali durante la conferenza. Gli investitori possono accedere a una registrazione della presentazione sul sito web di Journey Medical per circa 30 giorni dopo l'evento, offrendo un'opportunità di approfondire le strategie e le performance dell'azienda nel mercato farmaceutico dermatologico.
Journey Medical (Nasdaq: DERM), una compañía farmacéutica en etapa comercial especializada en tratamientos dermatológicos aprobados por la FDA, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. Claude Maraoui, Presidente y CEO, presentará una visión general de la empresa que estará disponible para visualización bajo demanda a partir del 9 de septiembre de 2024, a las 7:00 a.m. ET.
La compañía también participará en reuniones uno a uno durante la conferencia. Los inversores pueden acceder a una repetición de la presentación en el sitio web de Journey Medical durante aproximadamente 30 días después del evento, lo cual ofrece una oportunidad para conocer las estrategias y el rendimiento de la empresa en el mercado farmacéutico dermatológico.
Journey Medical (Nasdaq: DERM), FDA 승인 피부과 치료에 전문화된 상업 단계 제약 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. Claude Maraoui, 사장 겸 CEO가 2024년 9월 9일 오전 7시(ET)부터 주문형으로 제공되는 기업 개요를 발표할 것입니다.
또한, 회의 중에 개별 미팅도 진행할 예정입니다. 투자자들은 이벤트 후 약 30일 동안 Journey Medical 웹사이트에서 발표 재생을 접속할 수 있으며, 이를 통해 피부과 제약 시장에서 회사의 전략과 성과에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Journey Medical (Nasdaq: DERM), une entreprise pharmaceutique en phase commerciale spécialisée dans les traitements dermatologiques approuvés par la FDA, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. Claude Maraoui, Président-directeur général, présentera une vue d'ensemble de l'entreprise disponible en visionnage à la demande à partir de 9 septembre 2024, à 7h00 ET.
L'entreprise participera également à des réunions individuelles durant la conférence. Les investisseurs pourront accéder à un enregistrement de la présentation sur le site Web de Journey Medical pendant environ 30 jours après l'événement, offrant une occasion d'obtenir des informations sur les stratégies et les performances de l'entreprise sur le marché pharmaceutique dermatologique.
Journey Medical (Nasdaq: DERM), ein in der Vermarktungsphase befindliches Pharmaunternehmen, das sich auf von der FDA genehmigte dermatologische Behandlungen spezialisiert hat, hat seine Teilnahme an der 26. Jährlichen Globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Claude Maraoui, Präsident und CEO, wird eine Unternehmensübersicht präsentieren, die ab 9. September 2024 um 7:00 Uhr ET on-demand verfügbar ist.
Das Unternehmen wird außerdem an Einzelgesprächen während der Konferenz teilnehmen. Investoren haben die Möglichkeit, die Präsentation etwa 30 Tage nach der Veranstaltung auf der Website von Journey Medical anzusehen, was eine Gelegenheit bietet, Einblicke in die Strategien und Leistungen des Unternehmens im dermatologischen Pharmamarkt zu gewinnen.
- None.
- None.
SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference.
A replay of the presentation will be available shortly after the conference on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, for approximately 30 days after the meeting.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
When is Journey Medical (DERM) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Journey Medical (DERM) at the investment conference?
How long will the replay of Journey Medical 's (DERM) presentation be available?
What is the main focus of Journey Medical (DERM)?
